Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-27

Clinical Trial Update: Mepolizumab for the Treatment of Chronic Spontaneous Urticaria [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial evaluating mepolizumab for chronic spontaneous urticaria has completed enrollment and posted results in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nucala (mepolizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Chronic Spontaneous Urticaria | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2025-08-27